{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:51Z","timestamp":1791747951482,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chongqing Natural Science Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin resistance remains a major hurdle in non-small cell lung cancer (NSCLC) treatment. Here, we designed and synthesized a novel ruthenium-based compound, which selectively kills cisplatin-resistant NSCLC cells while sparing parental cells. Mechanistically, Ru3 triggers mitochondrial damage and reactive oxygen species (ROS) accumulation. In addition, it upregulates the transcription factor E2F2, which directly represses IGFBP3 expression. IGFBP3 normally scavenges ROS via the GPX4 system; thus, E2F2-mediated IGFBP3 suppression disrupts this antioxidant defense, exacerbating ROS levels and cell death. Notably, cisplatin-resistant cells exhibit elevated GPX4 and IGFBP3 expression, making them particularly vulnerable to Ru3. This study elucidates the E2F2-IGFBP3-GPX4 axis as a novel therapeutic vulnerability and highlights Ru3 as a promising agent for refractory NSCLC.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    Ru3's Mechanism of Action on Cisplatin Resistant Lung Cancer Cells\n                    <jats:list list-type=\"order\">\n                      <jats:list-item>\n                        <jats:p>Ru3 induces mitochondrial damage, which promotes the accumulation of ROS and ultimately triggers cell death.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Ru3 upregulates E2F2, enabling it to directly bind to the IGFBP3 promoter and suppress IGFBP3 expression, which inhibits GPX4 expression and further exacerbating lethal ROS accumulation .<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Treatment with Ru3 resulted in significant cell death in cisplatin-resistant lung cancer cells, yet had a minimal impact on parental lung cancer cells, which attributed to the suppression of the TRX antioxidant system in cisplatin-resistant cells, coupled with an increase in the activity of the GSH antioxidant system.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.1007\/s10495-026-02447-3","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:09:01Z","timestamp":1791050941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ru3: a novel ruthenium-based compound overcomes cisplatin resistance in non-small cell lung cancer via the E2F2-IGFBP3-GPX4 pathway"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6042-5448","authenticated-orcid":false,"given":"Yiting","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2447_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14737140.2018.1409624","volume":"18","author":"M Nagasaka","year":"2018","unstructured":"Nagasaka M, Gadgeel SM (2018) Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 18:63\u201370. https:\/\/doi.org\/10.1080\/14737140.2018.1409624","journal-title":"Expert Rev Anticancer Ther"},{"key":"2447_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/EDBK_175188","volume":"37","author":"SM Gadgeel","year":"2017","unstructured":"Gadgeel SM (2017) Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Am Soc Clin Oncol Educ Book 37:630\u2013639. https:\/\/doi.org\/10.1200\/EDBK_175188","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2447_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L et al (2024) Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA 331:201\u2013211. https:\/\/doi.org\/10.1001\/jama.2023.24735","journal-title":"JAMA"},{"key":"2447_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty WJ, Paz-Ares L (2023) Emerging strategies for the treatment of small cell lung cancer: a review. JAMA Oncol 9:419\u2013429. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5631","journal-title":"JAMA Oncol"},{"key":"2447_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"Y-L Wu","year":"2024","unstructured":"Wu Y-L, Dziadziuszko R, Ahn JS et al (2024) Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 390:1265\u20131276. https:\/\/doi.org\/10.1056\/NEJMoa2310532","journal-title":"N Engl J Med"},{"key":"2447_CR6","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jtcvs.2012.03.039","volume":"144","author":"S Heon","year":"2012","unstructured":"Heon S, Johnson BE (2012) Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 144:S39-42. https:\/\/doi.org\/10.1016\/j.jtcvs.2012.03.039","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2447_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"2447_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/ars.2021.0183","volume":"36","author":"AR Fetoni","year":"2022","unstructured":"Fetoni AR, Paciello F, Troiani D (2022) Cisplatin chemotherapy and cochlear damage: otoprotective and chemosensitization properties of polyphenols. Antioxid Redox Signal 36:1229\u20131245. https:\/\/doi.org\/10.1089\/ars.2021.0183","journal-title":"Antioxid Redox Signal"},{"key":"2447_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115618","volume":"426","author":"J Zeng","year":"2021","unstructured":"Zeng J, Zhao Y, Li K et al (2021) A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53\/AkT\/mTOR\/VEGF pathway. Toxicol Appl Pharmacol 426:115618. https:\/\/doi.org\/10.1016\/j.taap.2021.115618","journal-title":"Toxicol Appl Pharmacol"},{"key":"2447_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061412","volume":"9","author":"MG Ferraro","year":"2020","unstructured":"Ferraro MG, Piccolo M, Misso G et al (2020) Breast cancer chemotherapeutic options: a general overview on the preclinical validation of a multi-target ruthenium(III) complex lodged in nucleolipid nanosystems. Cells 9:1412. https:\/\/doi.org\/10.3390\/cells9061412","journal-title":"Cells"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/molecules25020265","volume":"25","author":"G Golbaghi","year":"2020","unstructured":"Golbaghi G, Castonguay A (2020) Rationally designed ruthenium complexes for breast cancer therapy. Molecules 25:265. https:\/\/doi.org\/10.3390\/molecules25020265","journal-title":"Molecules"},{"key":"2447_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/molecules24101995","volume":"24","author":"E Alessio","year":"2019","unstructured":"Alessio E, Messori L (2019) NAMI-A and KP1019\/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules 24:1995. https:\/\/doi.org\/10.3390\/molecules24101995","journal-title":"Molecules"},{"key":"2447_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108572","volume":"161","author":"D Duan","year":"2025","unstructured":"Duan D, Yang X, Guo X et al (2025) Interaction of glaucocalyxin a with glutathione and thioredoxin reductase for triple-negative breast cancer treatment. Bioorg Chem 161:108572. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108572","journal-title":"Bioorg Chem"},{"key":"2447_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18632\/aging.204466","volume":"15","author":"S-Y Wen","year":"2023","unstructured":"Wen S-Y, Ali A, Huang I-C et al (2023) Doxorubicin induced ROS-dependent HIF1\u03b1 activation mediates blockage of IGF1R survival signaling by IGFBP3 promotes cardiac apoptosis. Aging 15:164\u2013178. https:\/\/doi.org\/10.18632\/aging.204466","journal-title":"Aging"},{"key":"2447_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH (2022) The role of ROS in tumour development and progression. Nat Rev Cancer 22:280\u2013297. https:\/\/doi.org\/10.1038\/s41568-021-00435-0","journal-title":"Nat Rev Cancer"},{"key":"2447_CR16","unstructured":"ROS signalling in the biology of cancer - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28587975\/. Accessed 2 Nov 2023"},{"key":"2447_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147379","volume":"22","author":"M Wangpaichitr","year":"2021","unstructured":"Wangpaichitr M, Theodoropoulos G, Nguyen DJM et al (2021) Cisplatin resistance and redox-metabolic vulnerability: a second alteration. Int J Mol Sci 22:7379. https:\/\/doi.org\/10.3390\/ijms22147379","journal-title":"Int J Mol Sci"},{"key":"2447_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.annonc.2020.01.066","volume":"31","author":"N Murphy","year":"2020","unstructured":"Murphy N, Knuppel A, Papadimitriou N et al (2020) Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with \u223c430 000 women. Ann Oncol 31:641\u2013649. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.066","journal-title":"Ann Oncol"},{"key":"2447_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cen.13499","volume":"88","author":"YX Chan","year":"2018","unstructured":"Chan YX, Alfonso H, Paul Chubb SA et al (2018) Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1. Clin Endocrinol 88:333\u2013340. https:\/\/doi.org\/10.1111\/cen.13499","journal-title":"Clin Endocrinol"},{"key":"2447_CR20","unstructured":"Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/31884074\/. Accessed 5 Oct 2024"},{"key":"2447_CR21","doi-asserted-by":"publisher","first-page":"15043","DOI":"10.1007\/s13277-016-5400-8","volume":"37","author":"L Bao","year":"2016","unstructured":"Bao L, Liu H, You B et al (2016) Overexpression of IGFBP3 is associated with poor prognosis and tumor metastasis in nasopharyngeal carcinoma. Tumour Biol 37:15043\u201315052. https:\/\/doi.org\/10.1007\/s13277-016-5400-8","journal-title":"Tumour Biol"},{"key":"2447_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-021-01898-7","volume":"40","author":"S-H Wang","year":"2021","unstructured":"Wang S-H, Chen Y-L, Hsiao J-R et al (2021) Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-\u03baB\/IL-6\/ROS signaling. J Exp Clin Cancer Res 40:95. https:\/\/doi.org\/10.1186\/s13046-021-01898-7","journal-title":"J Exp Clin Cancer Res"},{"key":"2447_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1397303","volume":"15","author":"Y Gao","year":"2024","unstructured":"Gao Y, Qiao X, Liu Z, Zhang W (2024) The role of E2F2 in cancer progression and its value as a therapeutic target. Front Immunol 15:1397303. https:\/\/doi.org\/10.3389\/fimmu.2024.1397303","journal-title":"Front Immunol"},{"key":"2447_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.677111","volume":"11","author":"C Chen","year":"2021","unstructured":"Chen C, Zheng Q, Pan S et al (2021) The RNA-binding protein NELFE promotes gastric cancer growth and metastasis through E2F2. Front Oncol 11:677111. https:\/\/doi.org\/10.3389\/fonc.2021.677111","journal-title":"Front Oncol"},{"key":"2447_CR25","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202891","author":"H Li","year":"2021","unstructured":"Li H, Zhao S, Shen L et al (2021) E2F2 inhibition induces autophagy via the PI3K\/Akt\/mTOR pathway in gastric cancer. Aging. https:\/\/doi.org\/10.18632\/aging.202891","journal-title":"Aging"},{"key":"2447_CR26","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1038\/s41388-021-01855-w","volume":"40","author":"S Wang","year":"2021","unstructured":"Wang S, Cao K, Liao Y et al (2021) CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma. Oncogene 40:4368\u20134383. https:\/\/doi.org\/10.1038\/s41388-021-01855-w","journal-title":"Oncogene"},{"key":"2447_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2019.110869","volume":"202","author":"A Savi\u0107","year":"2020","unstructured":"Savi\u0107 A, Gligorijevi\u0107 N, Aran\u0111elovi\u0107 S et al (2020) Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenantroline: synthesis and biological activity. J Inorg Biochem 202:110869. https:\/\/doi.org\/10.1016\/j.jinorgbio.2019.110869","journal-title":"J Inorg Biochem"},{"key":"2447_CR28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/21691401.2017.1374285","volume":"46","author":"J Wang","year":"2018","unstructured":"Wang J, Chen Y, Xiang F et al (2018) Suppression of TGF-\u03b21 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins. Artif Cells Nanomed Biotechnol 46:1505\u20131512. https:\/\/doi.org\/10.1080\/21691401.2017.1374285","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2447_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/ijms19051479","volume":"19","author":"X Fan","year":"2018","unstructured":"Fan X, Wang Y, Jiang T et al (2018) B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci 19:1479. https:\/\/doi.org\/10.3390\/ijms19051479","journal-title":"Int J Mol Sci"},{"key":"2447_CR30","unstructured":"B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28555007\/. Accessed 5 Oct 2024"},{"key":"2447_CR31","unstructured":"M N, H K, S K, et al (2014) IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res 4"},{"key":"2447_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3725","author":"ET Hm","year":"2015","unstructured":"Hm ET, Aa W, Ra A et al (2015) Transcriptional activation of the IGF-II\/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2015.3725","journal-title":"Oncol Lett"},{"key":"2447_CR33","doi-asserted-by":"publisher","first-page":"D260","DOI":"10.1093\/nar\/gkx1126","volume":"46","author":"A Khan","year":"2018","unstructured":"Khan A, Fornes O, Stigliani A et al (2018) JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res 46:D260\u2013D266. https:\/\/doi.org\/10.1093\/nar\/gkx1126","journal-title":"Nucleic Acids Res"},{"key":"2447_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065920","volume":"24","author":"E Gentilin","year":"2023","unstructured":"Gentilin E (2023) New advancements in cisplatin-based treatments. Int J Mol Sci 24:5920. https:\/\/doi.org\/10.3390\/ijms24065920","journal-title":"Int J Mol Sci"},{"key":"2447_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107175","volume":"203","author":"K Li","year":"2024","unstructured":"Li K, Li J, Li Z et al (2024) Cisplatin-based combination therapies: their efficacy with a focus on ginsenosides co-administration. Pharmacol Res 203:107175. https:\/\/doi.org\/10.1016\/j.phrs.2024.107175","journal-title":"Pharmacol Res"},{"key":"2447_CR36","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/ijms23031532","volume":"23","author":"S Dasari","year":"2022","unstructured":"Dasari S, Njiki S, Mbemi A et al (2022) Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci 23:1532. https:\/\/doi.org\/10.3390\/ijms23031532","journal-title":"Int J Mol Sci"},{"key":"2447_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.actbio.2015.02.009","volume":"18","author":"C Shi","year":"2015","unstructured":"Shi C, Yu H, Sun D et al (2015) Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma. Acta Biomater 18:68\u201376. https:\/\/doi.org\/10.1016\/j.actbio.2015.02.009","journal-title":"Acta Biomater"},{"key":"2447_CR38","unstructured":"Ruthenium-based compounds and tumour growth control (review)\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/10891547\/. Accessed 30 Oct 2024"},{"key":"2447_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1124\/jpet.121.000798","volume":"380","author":"FV Gama Justi","year":"2022","unstructured":"Gama Justi FV, Ara\u00fajo Matos G, de S\u00e1 Roriz Caminha J et al (2022) The role of ruthenium compounds in neurologic diseases: a minireview. J Pharmacol Exp Ther 380:47\u201353. https:\/\/doi.org\/10.1124\/jpet.121.000798","journal-title":"J Pharmacol Exp Ther"},{"key":"2447_CR40","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2174\/092986706776360941","volume":"13","author":"I Kostova","year":"2006","unstructured":"Kostova I (2006) Ruthenium complexes as anticancer agents. Curr Med Chem 13:1085\u20131107. https:\/\/doi.org\/10.2174\/092986706776360941","journal-title":"Curr Med Chem"},{"key":"2447_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102339","volume":"53","author":"H Fan","year":"2022","unstructured":"Fan H, He Y, Xiang J et al (2022) ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy. Redox Biol 53:102339. https:\/\/doi.org\/10.1016\/j.redox.2022.102339","journal-title":"Redox Biol"},{"key":"2447_CR42","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.7150\/thno.34663","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou J, Zhang L, Wang M et al (2019) CPX targeting DJ-1 triggers ROS-induced cell death and protective autophagy in colorectal cancer. Theranostics 9:5577\u20135594. https:\/\/doi.org\/10.7150\/thno.34663","journal-title":"Theranostics"},{"key":"2447_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.semcdb.2012.03.017","volume":"23","author":"H Zhang","year":"2012","unstructured":"Zhang H, Forman HJ (2012) Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol 23:722\u2013728. https:\/\/doi.org\/10.1016\/j.semcdb.2012.03.017","journal-title":"Semin Cell Dev Biol"},{"key":"2447_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/ars.2007.9.25","volume":"9","author":"CH Lillig","year":"2007","unstructured":"Lillig CH, Holmgren A (2007) Thioredoxin and related molecules\u2013from biology to health and disease. Antioxid Redox Signal 9:25\u201347. https:\/\/doi.org\/10.1089\/ars.2007.9.25","journal-title":"Antioxid Redox Signal"},{"key":"2447_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.freeradbiomed.2005.04.025","volume":"39","author":"A-B Witte","year":"2005","unstructured":"Witte A-B, Anest\u00e5l K, Jerremalm E et al (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39:696\u2013703. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2005.04.025","journal-title":"Free Radic Biol Med"},{"key":"2447_CR46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.freeradbiomed.2007.06.021","volume":"43","author":"Y Lu","year":"2007","unstructured":"Lu Y, Cederbaum A (2007) The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic Biol Med 43:1061\u20131075. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2007.06.021","journal-title":"Free Radic Biol Med"},{"key":"2447_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.465","volume":"5","author":"CRR Rocha","year":"2014","unstructured":"Rocha CRR, Garcia CCM, Vieira DB et al (2014) Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505. https:\/\/doi.org\/10.1038\/cddis.2014.465","journal-title":"Cell Death Dis"},{"key":"2447_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers1010023","volume":"1","author":"M Wangpaichitr","year":"2009","unstructured":"Wangpaichitr M, Wu C, You M et al (2009) N\u2019, N\u2019-dimethyl-N\u2019, N\u2019-bis(phenylcarbonothioyl) propanedihydrazide (elesclomol) selectively kills cisplatin resistant lung cancer cells through reactive oxygen species (ROS). Cancers 1:23\u201338. https:\/\/doi.org\/10.3390\/cancers1010023","journal-title":"Cancers"},{"key":"2447_CR49","first-page":"29","volume":"4","author":"M Natsuizaka","year":"2014","unstructured":"Natsuizaka M, Kinugasa H, Kagawa S et al (2014) IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res 4:29\u201341","journal-title":"Am J Cancer Res"},{"key":"2447_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108984","volume":"27","author":"AR Leslie","year":"2024","unstructured":"Leslie AR, Ning S, Armstrong CM et al (2024) IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience 27:108984. https:\/\/doi.org\/10.1016\/j.isci.2024.108984","journal-title":"iScience"},{"key":"2447_CR51","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7150\/thno.87329","volume":"14","author":"SH Kang","year":"2024","unstructured":"Kang SH, Oh SY, Lee K-Y et al (2024) Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p. Theranostics 14:460\u2013479. https:\/\/doi.org\/10.7150\/thno.87329","journal-title":"Theranostics"},{"key":"2447_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030405","volume":"12","author":"K-L Coleman","year":"2023","unstructured":"Coleman K-L, Chiaramonti M, Haddad B et al (2023) Phosphorylation of IGFBP-3 by casein kinase 2 blocks its interaction with hyaluronan, enabling HA-CD44 signaling leading to increased NSCLC cell survival and cisplatin resistance. Cells 12:405. https:\/\/doi.org\/10.3390\/cells12030405","journal-title":"Cells"},{"key":"2447_CR53","unstructured":"E2F2 promotes lung adenocarcinoma progression through B-Myb- and FOXM1-facilitated core transcription regulatory circuitry - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35844795\/. Accessed 20 Nov 2024"},{"key":"2447_CR54","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1038\/s41388-021-01961-9","volume":"40","author":"X Fan","year":"2021","unstructured":"Fan X, Wang Y, Jiang T et al (2021) B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2. Oncogene 40:5613\u20135625. https:\/\/doi.org\/10.1038\/s41388-021-01961-9","journal-title":"Oncogene"},{"key":"2447_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01715-x","volume":"39","author":"Q Liu","year":"2022","unstructured":"Liu Q, Song C, Li J et al (2022) E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. Med Oncol 39:124. https:\/\/doi.org\/10.1007\/s12032-022-01715-x","journal-title":"Med Oncol"},{"key":"2447_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/genes14020393","volume":"14","author":"R Nakajima","year":"2023","unstructured":"Nakajima R, Zhao L, Zhou Y et al (2023) Deregulated E2F activity as a cancer-cell specific therapeutic tool. Genes 14:393. https:\/\/doi.org\/10.3390\/genes14020393","journal-title":"Genes"},{"key":"2447_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113198","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Armand J, Safonov A et al (2023) Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer. Cell Rep 42:113198. https:\/\/doi.org\/10.1016\/j.celrep.2023.113198","journal-title":"Cell Rep"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02447-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:48:53Z","timestamp":1791744533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02447-3","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human subjects. All animal experiments in this study were conducted compliance with animal protocols and approved by the Animal Ethics Committee of Chongqing Medical University (Certification Approval number:IACUC-CQMU-2024-0026).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors agree for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"243"}}